A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback